PCRX — Pacira BioSciences, Inc. · P/E 174, rev $369.8M

Pacira BioSciences, Inc. (PCRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.

Latest reported PCRX revenue for 2026-06-30 was $369.8M. Net income was $7.6M. PCRX currently screens at market cap $890.8M and trailing P/E 174.2.

Use this PCRX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PCRX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PCRX SEC filings page. Lician reads the product cache first so this HTML stays unique to Pacira BioSciences, Inc. even when a live quote feed is slow.

Pacira BioSciences, Inc. latest statements (FY2025)

Latest cached year on this hub. Full PCRX income, balance, and cash tables.

  • Revenue$726.4M
  • Net Income$7.0M
  • Total Assets$1.26B
  • Total Debt$0
  • Free Cash Flow$136.7M

PCRX recent filings